[1] Madabhavi I, Patel A, Sarkar M, Anand A, Panchal
H, Parikh S. A study of use of “PORT” catheter in patients
with cancer: A single-center experience. Clinical
Medicine Insights: Oncology. 2017; 11:1179554917691031.
[DOI:10.1177/1179554917691031] [PMID] [PMCID]
[2] Piran S, Ngo V, McDiarmid S, Le Gal G, Petrcich W,
Carrier M. Incidence and risk factors of symptomatic venous
thromboembolism related to implanted ports in
cancer patients. Thrombosis Research. 2014; 133(1):30-3.
[DOI:10.1016/j.thromres.2013.10.026] [PMID]
[3] LeVasseur N, Stober C, Daigle K, Robinson A, McDiarmid
S, Mazzarello S, et al. Optimizing vascular access for
patients receiving intravenous systemic therapy for earlystage
breast cancer-a survey of oncology nurses and physicians.
Current Oncology. 2018; 25(4):298-309. [DOI:10.3747/
co.25.3903] [PMID] [PMCID]
[4] Kakkos A, Bresson L, Hudry D, Cousin S, Lervat C, Bogart
E, et al. Complication-related removal of totally implantable
venous access port systems: Does the interval between
placement and first use and the neutropenia-inducing
potential of chemotherapy regimens influence their incidence?
A four-year prospective study of 4045 patients.
European Journal of Surgical Oncology. 2017; 43(4):689-95.
[DOI:10.1016/j.ejso.2016.10.020] [PMID]
[5] Silas AM, Perrich KD, Hoffer EK, McNulty NJ. Complication
rates and outcomes of 536 implanted subcutaneous
chest ports: Do rates differ based on the primary operator’s
level of training? Academic Radiology. 2010; 17(4):464-7.
[DOI:10.1016/j.acra.2009.10.019] [PMID]
[6] Narducci F, Jean-Laurent M, Boulanger L, El Bédoui S, Mallet
Y, Houpeau J, et al. Totally implantable venous access port systems
and risk factors for complications: A one-year prospective
study in a cancer centre. European Journal of Surgical Oncology.
2011; 37(10):913-8. [DOI:10.1016/j.ejso.2011.06.016] [PMID]
[7] Özdemir NY, Abalı H, Öksüzoğlu B, Budakoğlu B, Akmangit
İ, Zengin N. It appears to be safe to start chemotherapy on
the day of implantation through subcutaneous venous port
catheters in inpatient setting.Supportive Care in Cancer. 2009;
17(4):399-403. [DOI:10.1007/s00520-008-0498-x] [PMID]
[8] Ignatov A, Hoffman O, Smith B, Fahlke J, Peters B, Bischoff
J, et al. An 11-year retrospective study of totally implanted
central venous access ports: Complications and patient
satisfaction. European Journal of Surgical Oncology.
2009; 35(3):241-6. [DOI:10.1016/j.ejso.2008.01.020] [PMID]
[9] Ji L, Yang J, Miao J, Shao Q, Cao Y, Li H. Infections related
to totally implantable venous-access ports: Long-term experience
in one center. Cell Biochemistry and Biophysics. 2015;
72(1):235-40. [DOI:10.1007/s12013-014-0443-1] [PMID]
[10] Seok JP, Kim YJ, Cho HM, Ryu HY, Hwang WJ, Sung
TY. A retrospective clinical study: Complications of totally
implanted central venous access ports. The Korean Journal
of Thoracic and Cardiovascular Surgery. 2014; 47(1):26-44.
[DOI:10.5090/kjtcs.2014.47.1.26] [PMID] [PMCID]
[11] Ferlay J, Colombet M, Soerjomataram I, Parkin DM,
Piñeros M, Znaor A, et al. Cancer statistics for the year 2020:
An overview. International Journal of Cancer. 2021; 2(1):22-
9. [DOI:10.1002/ijc.33588] [PMID]
[12] Vardy J, Engelhardt K, Cox K, Jacquet J, McDade A,
Boyer M, et al. Long-term outcome of radiological-guided
insertion of implanted central venous access port devices
(CVAPD) for the delivery of chemotherapy in cancer patients:
Institutional experience and review of the literature.
British Journal of Cancer. 2004; 91(6):1045-9. [DOI:10.1038/
sj.bjc.6602082] [PMID] [PMCID]
[13] Damascelli B, Patelli G, Frigerio LF, LanoCita R, Garbagnati
F, Marchiano A, et al. Placement of long-term central
venous catheters in outpatients: Study of 134 patients over
24,596 catheter days. American Journal of Roentgenology.
1997; 168(5):1235-9. [DOI:10.2214/ajr.168.5.9129419] [PMID]
[14] Biffi R, De Braud F, Orsi F, Pozzi S, Mauri S, Goldhirsch
A, et al. Totally implantable central venous access ports for
long-term chemotherapy A prospective study analyzing
complications and costs of 333 devices with a minimum
follow-up of 180 days. Annals of Oncology. 1998; 9(7):767-
73.[DOI:10.1023/A:1008392423469] [PMID]
[15] Fornaro C, Piubeni M, Tovazzi V, Cosentini D, Gelmi M,
Rota G, et al. Eight‐week interval in flushing and locking
port‐a‐cath in cancer patients: A single‐institution experience
and systematic review. European Journal of Cancer
Care. 2019; 28(2):36-55. [DOI:10.1111/ecc.12978] [PMID]
[16] Wu X, Zhang T, Chen L, Chen X. Prolonging the flushlock
interval of totally implantable venous access ports in
patients with cancer: A systematic review and meta-anal-
ysis. The Journal of Vascular Access. 2021; 22(5):814-21.
[DOI:10.1177/1129729820950998]
[17] Narducci F, Jean-Laurent M, Boulanger L, El Bédoui S,
Mallet Y, Houpeau J, et al. Totally implantable venous access
port systems and risk factors for complications: A oneyear
prospective study in a cancer centre. European Journal
of Surgical Oncology. 2011; 37(10):913-8. [DOI:10.1016/j.
ejso.2011.06.016] [PMID]
[18] Lorch H, Zwaan M, Kagel C, Weiss H-D. Central venous
access ports placed by interventional radiologists: Experience
with 125 consecutive patients. CardioVascular and
Interventional Radiology. 2001; 24(3):180-4. [DOI:10.1007/
s002700001721] [PMID]
[19] Biacchi D, Sammartino P, Sibio S, Accarpio F, Cardi
M, Sapienza P, et al. Does the implantation technique for
totally implantable venous access ports (TIVAPs) influence
long-term outcome? World Journal of Surgery. 2016;
40(2):284-90. [DOI:10.1007/s00268-015-3233-z] [PMID]
[20] Kock H-J, Pietsch M, Krause U, Wilke H, Eigler F. Implantable
vascular access systems: Experience in 1500 patients
with totally implanted central venous port systems.
World Journal of Surgery. 1998; 22(1):12-6. [DOI:10.1007/
s002689900342] [PMID]
)